Dataset Information
LC-MS-Based Quantitative Proteomic Profiling Reveals WWQ-03-012-Induced Alterations in Protein Expression of Human HEL Cells
Ontology highlight
ABSTRACT:
INSTRUMENT(S):
ORGANISM(S): Homo Sapiens (human)
TISSUE(S): Blood Cell
DISEASE(S): Acute Leukemia
SUBMITTER: 
Mei Husheng
LAB HEAD: Jing Yang
PROVIDER: PXD065708 | Pride | 2026-02-09
REPOSITORIES: Pride
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| YAS202412200028-1-HEL-1.raw | Raw | |||
| YAS202412200028-1-HEL-2.raw | Raw | |||
| YAS202412200028-1-HEL-3.raw | Raw | |||
| YAS202412200028-1-HEL03-1.raw | Raw | |||
| YAS202412200028-1-HEL03-2.raw | Raw |
Items per page: 1 - 5 of 12 |
Publications
Targeting DESI2 as a Novel Therapeutic Strategy for JAK2-Mutant Leukemias.
Advanced science (Weinheim, Baden-Wurttemberg, Germany) 20251203 7
The JAK2-V617F mutation is the most common genetic alteration in myeloproliferative neoplasms (MPN), which can progress to secondary acute myeloid leukemia (sAML), a chemotherapy-resistant disease with limited treatment options and a poor prognosis. Although the JAK1/2 inhibitor Ruxolitinib is clinically approved, its efficacy is limited by toxicity to normal cells and the development of drug resistance. Here, the deSUMOylase DESI2 is identified as a novel component of the JAK2-V617F complex by ...[more]